MANA Therapeutics, a clinical-stage company creating nonengineered, off-the-shelf allogeneic cell therapies that target multiple cancer antigens, has raised a $35 million Series A financing. The financing was led by Cobro Ventures and Lightchain Capital, with participation from LifeSci Venture Partners and other undisclosed investors.

MANA Therapeutics is harnessing the natural immune system to develop broadly accessible, ready-to-use cellular therapies to improve outcomes for cancer patients. By educating T-cells to target multiple tumor associated antigens without the need for genetic modification, MANA's EDIFY platform provides the opportunity to deliver safe, effective, and repeatable therapies.